匹立尼酸
匹立尼酸结构式
|
常用名 | 匹立尼酸 | 英文名 | Wy-14643 |
|---|---|---|---|---|
| CAS号 | 50892-23-4 | 分子量 | 323.798 | |
| 密度 | 1.4±0.1 g/cm3 | 沸点 | 514.4±50.0 °C at 760 mmHg | |
| 分子式 | C14H14ClN3O2S | 熔点 | 155°C | |
| MSDS | 美版 | 闪点 | 264.9±30.1 °C | |
| 符号 |
GHS07, GHS08 |
信号词 | Danger |
|
Activation of peroxisome proliferator activated receptor alpha ameliorates ethanol mediated liver fibrosis in mice.
Lipids Health Dis. 12 , 11, (2013) Peroxisome proliferator activated receptor alpha (PPARα) ameliorates ethanol induced hepatic steatohepatitis. However, its role in alcoholic liver fibrosis has not been fully clarified. The aim of this study was to elucidate the effect and the molecular basis... |
|
|
Muscle lipogenesis balances insulin sensitivity and strength through calcium signaling.
J. Clin. Invest. 123(3) , 1229-40, (2013) Exogenous dietary fat can induce obesity and promote diabetes, but endogenous fat production is not thought to affect skeletal muscle insulin resistance, an antecedent of metabolic disease. Unexpectedly, the lipogenic enzyme fatty acid synthase (FAS) was incr... |
|
|
Genetic ablation of solute carrier family 7a3a leads to hepatic steatosis in zebrafish during fasting.
Hepatology 60(6) , 1929-41, (2014) Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disorder caused by abnormal lipid metabolisms, such as reduced hepatic fatty acid oxidation (FAO), but intracellular control of FAO under physio- and pathological conditions remains lar... |
|
|
PPAR-alpha activation as a preconditioning-like intervention in rats in vivo confers myocardial protection against acute ischaemia-reperfusion injury: involvement of PI3K-Akt.
Can. J. Physiol. Pharmacol. 90(8) , 1135-44, (2012) Peroxisome proliferator-activated receptors (PPAR) regulate the expression of genes involved in lipid metabolism, energy production, and inflammation. Their role in ischaemia-reperfusion (I/R) is less clear, although research indicates involvement of PPARs in... |
|
|
Peroxisome proliferator-activated receptor-alpha agonists repress expression of thrombin-activatable fibrinolysis inhibitor by decreasing transcript stability.
Thromb. Haemost. 108(1) , 74-85, (2012) Thrombin-activatable fibrinolysis inhibitor (TAFI) (carboxypeptidase B2) is a plasma zymogen that is biosynthesised in the liver and released into the circulation. Activated TAFI is a prothrombotic factor which inhibits fibrin clot lysis. Cultured human hepat... |
|
|
Activation of peroxisome proliferator activated receptor alpha ameliorates ethanol induced steatohepatitis in mice.
Lipids Health Dis. 10 , 246, (2011) Peroxisome proliferator activated receptor alpha (PPARα) regulates lipids metabolism and inhibits inflammatory response. However, the role of PPARα in alcoholic liver disease is largely unknown. We aim to elucidate the effect and the molecular basis of PPARα ... |
|
|
Treatment with pharmacological PPARα agonists stimulates the ubiquitin proteasome pathway and myofibrillar protein breakdown in skeletal muscle of rodents.
Biochim. Biophys. Acta 1830(1) , 2105-17, (2013) Treatment of hyperlipidemic patients with fibrates, agonists of peroxisome proliferator-activated receptor α (PPARα), provokes muscle atrophy as a side effect. The molecular mechanism underlying this phenomenon is still unknown. We tested the hypothesis that ... |
|
|
Organotypic modeling of human keratinocyte response to peroxisome proliferators.
Cells Tissues Organs 196(5) , 431-41, (2012) Peroxisome proliferators (PPs) are a diverse chemical group including hypolipidemic drugs and some fatty acids. Their stimulation of PP-activated receptors (PPARs) and subsequent control of gene expression regulates metabolism and differentiation in many cell... |
|
|
In vivo imaging reveals selective PPAR activity in the skin of peroxisome proliferator-activated receptor responsive element-luciferase reporter mice.
Exp. Dermatol. 22(2) , 137-40, (2013) Peroxisome proliferator-activated receptors (PPARs) have been revealed as key regulators of several skin disorders. This has led to a growing interest in the development of drugs targeting PPARs as therapeutics for skin diseases. To evaluate skin PPAR activit... |
|
|
Fenofibrate down-regulates renal OCT2-mediated organic cation transport via PPARα-independent pathways.
Drug Metab. Pharmacokinet. 27(5) , 513-9, (2012) Fibrate drugs, the peroxisome proliferator-activated receptor alpha (PPARα) agonists, are widely prescribed for the treatment of hyperlipidemia. The present study examined the effect of fibrate drugs on renal OCT2 activity in a heterologous cell system [Chine... |